JG
ARCT icon

Jefferies Group’s Arcturus Therapeutics ARCT Stock Holding History

Jefferies Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,000
Closed -$781K – 1608
2020
Q4 		$781K Buy
+18,000
New +$1.22M 0.01% 1009
2017
Q1 		– Sell
-10,529
Closed -$155K – 2305
2016
Q4 		$155K Sell
10,529
-11,814
-53% -$177K ﹤0.01% 1954
2016
Q3 		$386K Buy
+22,343
New +$722K ﹤0.01% 1721
2014
Q4 		– Sell
-7,143
Closed -$772K – 1920
2014
Q3 		$772K Buy
+7,143
New +$931K 0.01% 1122

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Group's ARCT Position: Q1 2021 in Review

Jefferies Group sold out of Arcturus Therapeutics (ARCT) in Q1 2021, closing a stake of 3,076 shares — an estimated $133K sold.

Jefferies Group first reported a position in ARCT in Q3 2014 and held it in 6 quarters. The position peaked at $536K in Q3 2020. 162 funds tracked by Wall St. Rank hold ARCT as of Q1 2021.

  • Jefferies Group reported no remaining Arcturus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Jefferies Group sold 3,076 Arcturus Therapeutics shares in Q1 2021, an estimated $133K.
  • Jefferies Group first reported a position in Arcturus Therapeutics in Q3 2014 and held it in 6 quarters.
  • Jefferies Group's Arcturus Therapeutics position peaked at $536K in Q3 2020.
  • 162 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.